Exagen: A Small Diagnostics Company Approaching An Inflection Point

Exagen earns a Buy rating as revenue growth accelerates, ASPs improve, and break-even appears within reach despite ongoing cash burn. XGN leverages a growing proprietary autoimmune diagnostics database, positioning itself for long-term strategic value through AI-driven insights and biopharma partnerships. Gross margins remain stable near 60%, with breakeven targeted at $80M in sales and 63% margins, achievable by 2027 if 10% annual growth continues. Trading below 2x EV/Sales, XGN offers 75% upside potential to an $8–9/share 2028 target, though risks include execution, reimbursement, and dilution.

Exagen (XGN) is becoming a very interesting diagnostics company as revenue growth accelerates, average selling prices are improving, and management moves closer to its break-even target. While the business still burns cash and execution risks remain, I believe the market is